Barbara A. Munder
Director, Board of Directors
Ms. Munder became a Director for Sucampo in February 2013. She currently serves as Senior Advisor at Institutional Investor LLC, an international business-to-business publisher. She previously served as Executive Director of The Hedge Fund Institutional Forum at Institutional Investor LLC until 2005 and was a principal of Munder & Associates, a marketing and web-strategy consulting firm, from 2001 to 2002. Also in 2001, Ms. Munder served as Chief Operating Officer at Womenfuture LLC, a distance learning company, where she oversaw e-business strategy. From 1994 to 2000, Ms. Munder held various positions with The McGraw-Hill Companies, Inc., including Senior Vice President of New Initiatives, overseeing corporate-wide electronic commerce, and Senior Vice President of Corporate Affairs, responsible for branding, marketing, communications and Washington affairs.
Ms. Munder currently serves as a Director for Munder Realty Corporation, a private real estate firm. Previously, she served as a Director for PetSmart Inc. She has been on the advisory board for DOAR, a private litigation information services and consulting firm, Izzo Systems, a manufacturer of ergonomically designed golf bags and straps, and Lighthouse International, a non-profit for the visually impaired.
Ms. Munder earned a bachelor’s degree in political science from Elmira College and a master’s degree in business administration with a concentration in finance from Stern School of Business Administration at New York University.
Sucampo Pharmaceuticals, Inc. is focused on the development and commercialization of specialized medicines that meet major unmet medical needs of patients worldwide. Sucampo has two marketed products – AMITIZA, its lead product, and RESCULA – and a late-stage pipeline of product candidates in clinical development for orphan disease areas. VTS-270 is a mixture of 2-hydroxypropyl-B-cyclodextrins with a specific compositional fingerprint that has been granted orphan designation in the U.S. and Europe and is in a pivotal Phase 2/3 clinical trial for the treatment of Niemann-Pick Disease Type C-1. Sucampo has an option for the North American rights to CPP1- x/sulindac, which is in Phase 3 development for the treatment of familial adenomatous polyposis and has been granted orphan drug designation in the U.S. A global company, Sucampo is headquartered in Rockville, Maryland, and has operations in Japan and Switzerland.